CP-751,871

DRUG14 trials

Sponsors

Pfizer, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Suzanne George, MD

Conditions

Advanced CancerAdvanced Non-Hematologic MalignanciesAdvanced Solid TumorsBreast CancerBreast NeoplasmsCarcinoma, Non-Small-Cell LungEwing's Sarcoma Family of TumorsHead and Neck Cancer

Phase 1

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

CompletedNCT00147537

PfizerCarcinoma, Non-Small-Cell Lung

Start: 2005-02-28End: 2011-08-31Updated: 2013-10-30

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

CompletedNCT00474760

PfizerSarcoma, Ewing's

Start: 2005-08-31End: 2012-10-31Updated: 2013-12-17

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

CompletedNCT00560235

PfizerEwing's Sarcoma Family of Tumors

Start: 2008-03-31End: 2012-10-31Updated: 2015-10-28

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

CompletedNCT00560573

PfizerCarcinoma, Non-Small-Cell Lung

Start: 2007-11-30End: 2010-03-31Updated: 2013-03-21

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

TerminatedNCT00729833

PfizerAdvanced Cancer, Advanced Solid Tumors

Start: 2008-09-30End: 2013-04-30Updated: 2014-06-09

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

TerminatedNCT00926263

PfizerHealthy Volunteers

Start: 2009-07-31End: 2010-05-31Updated: 2013-05-07

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

CompletedNCT00927966

Suzanne George, MDSarcoma, Solid Tumor

Start: 2009-07-31End: 2011-01-31Updated: 2013-11-14

CP-751,871 Treatment For Patients With Multiple Myeloma

CompletedNCT01536145

PfizerMultiple Myeloma

Start: 2003-12-31End: 2008-06-30Updated: 2013-03-15

CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

CompletedNCT01653158

PfizerAdvanced Non-Hematologic Malignancies

Start: 2005-03-31End: 2009-02-28Updated: 2013-10-30

Phase 2

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

CompletedNCT00313781

PfizerProstatic Neoplasms

Start: 2006-05-31End: 2011-12-31Updated: 2013-04-11

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

TerminatedNCT00372996

PfizerBreast Neoplasms

Start: 2007-02-28End: 2014-06-30Updated: 2015-10-28

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

WithdrawnNCT00678626

PfizerBreast Cancer

Start: 2009-04-30End: 2011-09-30Updated: 2015-05-04

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

TerminatedNCT00872404

Cliniques universitaires Saint-Luc- Université Catholique de LouvainHead and Neck Cancer

Start: 2009-01-31End: 2010-09-30Updated: 2016-04-20

Phase 3

Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

WithdrawnNCT00907504

PfizerCarcinoma, Non-Small-Cell Lung

Start: 2010-07-31End: 2014-05-31Updated: 2014-06-17

Related Papers

Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature.

2025-11-19

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

2009-12-23262 citations